Featured Research

from universities, journals, and other organizations

Using maths, researchers seek to improve success in transplants

Date:
December 24, 2013
Source:
Investigación y Desarrollo
Summary:
Given that 10.5 % of patients who receive a transplant reject the new organ, researchers are working in the design of a tool capable of preventing this problem. The process consists in knowing the type of proteins in charge of metabolizing the drugs (enzymes) for each patient which would, helped by a mathematical model, allow to establish the exact dose needed of the immunosuppressive drugs required.

Given that 10.5 % of patients who receive a transplant reject the new organ, researchers at the Center of Research and Advanced Studies of the National Polytechnic Institute (Cinvestav) are working in the design of a tool capable of preventing this problem. The process consists in knowing the type of proteins in charge of metabolizing the drugs (enzymes) for each patient which would, helped by a mathematical model, allow to establish the exact dose needed of the immunosuppressive drugs required.

Related Articles


This method will be capable of giving an effective certainty at the moment of establishing the treatment, will also save time and decrease rejection, increasing the quality of life, allowing the survival of more patients and optimizing the health system, informed Gilberto Castañeda Hernández from the department of Pharmacology.

According to the researcher, the enzymes that process the drugs have various grades of activity, so the immunosuppressive can be eliminated slowly or rapidly. Hence, the necessity of knowing, using genetic studies, what kind of proteins each person has to determine the adequate portion of the drug.

Every study is being carried in order to create a mathematical algorithm that will indicate for each person, using their genetics, size, age, current medication and time since the transplant, what should their immunosuppressive drug dosage should be.

Currently, the quantity of drug to be administrated is determined by trial and error; however, this process takes long and gives place to complications that are translated to an acute rejection.

"For example, the dosage that is used in Germany of the drug Nifedipine is not adequate for Mexicans because it gives them headaches, tachycardia and vasodilation, among other problems," says Castañeda Hernández.

The challenge will be to identify the patients that quickly metabolize the immunosuppressive such as Tacrolimus and Ciclosporin. "In Mexico both exist and its dosage is not the same as used in Europe or the United States; we have to find our own genetic variations."

In Mexico, a window of opportunity is to apply this system to kids, making it possible to determine the immunosuppressive treatment correctly. The child population has a special metabolism because of its development; hence, applying the analysis tools would have better results, assured Castañeda Hernández.


Story Source:

The above story is based on materials provided by Investigación y Desarrollo. Note: Materials may be edited for content and length.


Cite This Page:

Investigación y Desarrollo. "Using maths, researchers seek to improve success in transplants." ScienceDaily. ScienceDaily, 24 December 2013. <www.sciencedaily.com/releases/2013/12/131224183545.htm>.
Investigación y Desarrollo. (2013, December 24). Using maths, researchers seek to improve success in transplants. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2013/12/131224183545.htm
Investigación y Desarrollo. "Using maths, researchers seek to improve success in transplants." ScienceDaily. www.sciencedaily.com/releases/2013/12/131224183545.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) — NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) — A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) — Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) — The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins